Literature DB >> 7876127

The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPAR alpha and thyroid hormone receptors.

L Jow1, R Mukherjee.   

Abstract

We have cloned two human peroxisome proliferator-activated receptor (PPAR) subtypes, hPPAR alpha and hNUC1. hPPAR alpha is activated by clofibric acid and other PPAR activators. hNUC1 is not activated by these compounds acting instead as a repressor of hPPAR alpha and human thyroid hormone receptor transcriptional activation. Repression is specific since hNUC1 does not significantly repress activation by the progesterone or retinoic acid receptors. We demonstrate co-operative binding of hNUC1 and hRXR alpha to a PPAR-responsive element and show that in the presence of hRXR alpha, the affinity of hNUC1 for the peroxisome proliferator is comparable to that of hPPAR alpha. Furthermore, repression of hPPAR alpha can be overcome by transfecting excess hPPAR alpha. We propose that hNUC1 represses the activity of hPPAR alpha by titrating out a factor required for activation. Our data further suggests convergence of thyroid hormone- and peroxisome-mediated fatty acid metabolism pathways. Overcoming hNUC1 repression could be a means of increasing the activity of these receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876127     DOI: 10.1074/jbc.270.8.3836

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita.

Authors:  M Ito; R Yu; J L Jameson
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

Review 2.  Regulation of cytochrome P450 (CYP) genes by nuclear receptors.

Authors:  P Honkakoski; M Negishi
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

3.  Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma.

Authors:  Rex C Haydon; Lan Zhou; Tao Feng; Benjamin Breyer; Hongwei Cheng; Wei Jiang; Akira Ishikawa; Terrance Peabody; Anthony Montag; Michael A Simon; Tong-Chuan He
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

4.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

Authors:  T C He; T A Chan; B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

Review 5.  Peroxisome proliferator-activated receptors in the cardiovascular system.

Authors:  D Bishop-Bailey
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 6.  PPARalpha: energy combustion, hypolipidemia, inflammation and cancer.

Authors:  Sean R Pyper; Navin Viswakarma; Songtao Yu; Janardan K Reddy
Journal:  Nucl Recept Signal       Date:  2010-04-16

7.  Differential alterations of ethanolamine and choline phosphoglyceride metabolism by clofibrate and retinoic acid in human fibroblasts are not mediated by phorbol ester-sensitive protein kinase C.

Authors:  S G Mandla; D M Byers; N D Ridgway; H W Cook
Journal:  Lipids       Date:  1996-07       Impact factor: 1.880

8.  Induction and repression of peroxisome proliferator-activated receptor alpha transcription by coregulator ARA70.

Authors:  Cynthia A Heinlein; Chawnshang Chang
Journal:  Endocrine       Date:  2003-07       Impact factor: 3.633

9.  Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor gamma activation induced by 15-deoxyDelta12,14-prostaglandin J2 in neuroblastoma cells.

Authors:  Helen A Rodway; Alan N Hunt; Janice A Kohler; Anthony D Postle; Karen A Lillycrop
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 10.  Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate.

Authors:  R J Bull
Journal:  Environ Health Perspect       Date:  2000-05       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.